T-DXd (Enhertu) PBPK-PD ILD Risk Simulator
Indication: HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, NSCLC, and other HER2-expressing solid tumors; ILD risk stratification and dose optimization
Interactive PBPK-PD simulator for T-DXd (Enhertu, trastuzumab deruxtecan) predicting DXd lung exposure and ILD risk probability across doses (3.2–6.4 mg/kg) and patient age (50–80 years). Based on the Wang et al. 2025 mechanistic PBPK model. Essential tool for understanding interstitial lung disease risk stratification in HER2-targeted ADC therapy.
Drug Overview
Clinical Context
- Molecular Target
- HER2 (ERBB2)
- Drug Class
- Antibody-Drug Conjugate (ADC)
- Therapeutic Area
- Oncology / Breast Cancer
- Indication
- HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, NSCLC, and other HER2-expressing solid tumors; ILD risk stratification and dose optimization
- Route of Administration
- IV Infusion
Model Information
- Model Type
- PBPK-PD
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
Additional Parameters
| Parameter | Value |
|---|---|
| DXd Lung IC10 | 17 |
| DXd Lung IC20 | 38.25 |
| DXd Lung IC50 | 153 |
| T-DXd Clearance (CL) | 0.42 |
| DXd Yield per ADC (FGEN) | 4.1 |
| T-DXd Central Volume (V1) | 2.68 |
| ADC Lung Uptake Rate (KIN L) | 0.0058 |
| T-DXd Peripheral Volume (V2) | 2.06 |
| DXd Lung Efflux Rate (KOUT L) | 0.05 |
| Endosomal Processing Rate (KPROC) | 0.0085 |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for T-DXd (Enhertu) PBPK-PD ILD Risk allows you to explore concentration-time profiles under different dosing scenarios. The underlying PBPK-PD model characterizes the pharmacokinetics of this antibody-drug conjugate (adc) following iv infusion administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the T-DXd (Enhertu) PBPK-PD ILD Risk PK simulator?
This is a free, interactive pharmacokinetic simulator for T-DXd (Enhertu) PBPK-PD ILD Risk used in HER2-positive metastatic breast cancer, gastric/GEJ adenocarcinoma, NSCLC, and other HER2-expressing solid tumors; ILD risk stratification and dose optimization. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does T-DXd (Enhertu) PBPK-PD ILD Risk belong to?
T-DXd (Enhertu) PBPK-PD ILD Risk is classified as a Antibody-Drug Conjugate (ADC) that targets HER2 (ERBB2). It is used in the Oncology / Breast Cancer therapeutic area.
What route of administration does this model simulate?
This simulator models IV Infusion administration of T-DXd (Enhertu) PBPK-PD ILD Risk. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PBPK-PD model. PBPK models use physiological parameters to predict drug distribution across tissues and organs.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Mirvetuximab Soravtansine (ELAHERE) PopPK
FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; maytansinoid DM4 payload
Patritumab Deruxtecan (HER3-DXd) PopPK
EGFR-mutant NSCLC after EGFR TKI and platinum therapy; HER3-directed ADC with DXd payload
PBPK-PD of ADCs
Trodelvy PopPK
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Datroway PopPK
Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload
Enhertu PopPK
HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC
Ready to Simulate?
Launch the T-DXd (Enhertu) PBPK-PD ILD Risk simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community